XM không cung cấp dịch vụ cho cư dân của Mỹ.
G
G

GSK


Tin tức

German panel endorses GSK, Pfizer RSV vaccines for elderly

German panel endorses GSK, Pfizer RSV vaccines for elderly FRANKFURT, Aug 8 (Reuters) - Germany's influential vaccine advisory panel said on Thursday that everyone in the country who is 75-years old or more should receive one of two new vaccines against the common respiratory infection RSV. The panel of independent experts known as STIKO said in a statement that one shot, either Pfizer's PFE.N Abrysvo or Arexvy by GSK GSK.L , should be administered ideally in September or October before the cold
A
G
P
S

UK Stocks-Factors to watch on August 8

UPDATE 1-UK Stocks-Factors to watch on August 8 Adds new items, updates futures Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.3%. * BARRATT-REDROW DEAL: UK's competition regulator said its phase 1 review into homebuilder Barratt's BDEV.L 2.52 billion pound ($3.21 billion) all-stock deal to buy smaller rival Redrow RDW.L had raised concerns in the local area around a Barratt development.
A
A
B
B
B
B
F
G
I
I
P
P
R
R
S
S

UK Stocks-Factors to watch on August 8

UK Stocks-Factors to watch on August 8 Aug 8 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.5%. * GSK: The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
A
A
B
B
B
D
F
G
H
I
I
L
P
P
P
R
S
S
U

Third trial over Zantac cancer claims ends with hung jury

UPDATE 1-Third trial over Zantac cancer claims ends with hung jury Adds response from plaintiff's attorney in paragraphs 2-3 By Brendan Pierson Aug 7 (Reuters) - The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer.
G
P
S

Third trial over Zantac cancer claims ends with hung jury

Third trial over Zantac cancer claims ends with hung jury By Brendan Pierson Aug 7 (Reuters) - The third trial over claims that discontinued heartburn drug Zantac ended in a mistrial on Wednesday when jurors could not agree about whether pharmaceutical company Boehringer Ingelheim was responsible for an Illinois man's cancer, according to the plaintiff's lawyer.
G
P
S

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes BENGALURU, Aug 7 (Reuters) - Drugmaker Abbott India ABOT.NS reported a rise in first-quarter profit on Wednesday, helped by higher sales and price hikes. The company, which makes the popular antacid medicine Digene, said its profit rose to 3.28 billion rupees ($39.1 million) for the quarter ended June 30, a 13% rise from last year.
A
G
P

Jefferies cuts SOBI to 'hold' as competition weighs

BUZZ-Jefferies cuts SOBI to 'hold' as competition weighs ** Jefferies cuts Swedish Orphan Biovitrum SOBIV.ST to "hold" from "buy", citing increasing competition pressure for the Swedish drug maker ** Brokerage sees Merck's MRK.N positive data for antibody against lung infections caused by respiratory syncytial virus (RSV), clesrovimab, as a downsid
G
S

UK Stocks-Factors to watch on Aug 6

UK Stocks-Factors to watch on Aug 6 Aug 6 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 1.2%. * IHG: Holiday Inn-owner InterContinental Hotels Group IHG.L reported a 3.2% rise in revenue per available room (RevPAR) in the second quarter as a strong rebound in the United States offset weakness in China.
B
G
H
T
U

GSK wins latest trial over Zantac cancer claims

GSK wins latest trial over Zantac cancer claims By Brendan Pierson Aug 5 (Reuters) - GSK GSK.L won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spokesperson said. Carrie Joiner had alleged in her lawsuit in state court in Chicago that she developed colorectal cancer from a carcinogenic contaminant called NDMA found in the once-blockuster drug.
G
P
S

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand BENGALURU, Aug 2 (Reuters) - India's GlaxoSmithKline Pharmaceuticals GLAX.NS reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British drugmaker GSK GSK.L reported a consolidated profit before tax and exceptional items of 2.49 billion rupees ($29.7 million) for the quarter ended June 30, compared with a profit of 1.64 billion rupe
A
G
P

GSK Says FDA Expands Jemperli Approval

BRIEF-GSK Says FDA Expands Jemperli Approval Aug 2 (Reuters) - GSK plc GSK.L : FDA EXPANDS JEMPERLI APPROVAL JEMPERLI APPROVAL NOW INCLUDES MMRP/MSS TUMOURS Source text for Eikon: ID:nRSB8948Ya Further company coverage: GSK.L
G

India economic, corporate events on August 2

DIARY- India economic, corporate events on August 2 BENGALURU, Aug 2 (Reuters) - Diary of India economic, corporate events on August 2. ECONOMIC, CORPORATE .BSE500 EVENTS: Start Date Start Time RIC Company Name Event Name 02-Aug-2024 NTS BRIT.NS Britannia Industries Ltd Q1 2025 Britannia Industries Ltd Earnings Release 02-Aug-2024 NTS GLAX.NS Glaxo
G

Danske Bank, Greggs, HSBC

EUROPE RESEARCH ROUNDUP-Danske Bank, Greggs, HSBC Aug 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Danske Bank, Greggs, and HSBC, on Thursday. HIGHLIGHTS * Danske Bank DANSKE.CO : HSBC raises target price to DKK 258 from DKK 257 * Greggs GRG.L : Berenberg raises target price to 3600p from 3340p * HSBC HSBA.L : Berenberg raises target price to 870p from 830p * Kardex Holding AG KARN.S : Berenberg raises target price to CHF 260
A
A
A
A
A
B
B
C
C
C
D
F
G
G
H
L
T
W
A
D
S

GSK plc reports results for the quarter ended in June - Earnings Summary

GSK plc reports results for the quarter ended in June - Earnings Summary GSK plc GSK.L reported quarterly adjusted earnings of 43 pence​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 39 pence. The mean expectation of eight analysts for the quarter was for earnings of 38 pence per share.
G

GSK slips on vaccine sales miss; cuts vaccine sales outlook

BUZZ-GSK slips on vaccine sales miss; cuts vaccine sales outlook ** Shares of GSK GSK.L down 2.6% at 1,502 pence; top loser on the FTSE 100 index ** Posts a 9% miss in vaccine sales after Shingrix sales missed consensus due to the U.S. demand weakness including destocking and a weaker sales outside the U.S. according to Jefferies ** Sees vaccine sa
G
U

GSK plc reports results for the quarter ended in January - Earnings Summary

GSK plc reports results for the quarter ended in January - Earnings Summary GSK plc GSK.N reported quarterly adjusted earnings of $1.10​​ per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of 97 cents. The mean expectation of two analysts for the quarter was for earnings of 98 cents per share.
G

Europe before the bell: appetite for tech, bank results

LIVE MARKETS-Europe before the bell: appetite for tech, bank results Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPE BEFORE THE BELL: APPETITE FOR TECH, BANK RESULTS Even though Microsoft MSFT.O failed to impress high Wall Street expectations, with growth in its cloud business falling a little short of what analysts had estimated, appetite for tech looked strong again on W
G
H
L
M
S
A
E
F
U
G

UK Stocks-Factors to watch on July 31

UPDATE 1-UK Stocks-Factors to watch on July 31 Adds new items, updates futures July 31 - Britain's FTSE 100 .FTSE index is seen opening higher on Wednesday, with futures FFIc1 up 0 .8%. * GSK: British drugmaker GSK GSK.L raised its annual earnings and sales forecasts and posted second-quarter results that beat market expectations, boosted by its cancer and HIV portfolio.
F
G
H
R
T

GSK Sees 2024 Turnover Growth Increase Of 7% To 9%

BRIEF-GSK Sees 2024 Turnover Growth Increase Of 7% To 9% July 31 (Reuters) - GSK plc GSK.L : GSK PLC - 2ND QUARTER RESULTS GSK: 2024 TURNOVER GROWTH INCREASE OF 7% TO 9% GSK - Q2 2024 DIVIDEND OF 15P DECLARED GSK SEES FY CORE OPERATING PROFIT GROWTH OF 11% TO 13% GSK SEES FY CORE EPS GROWTH OF 10% TO 12% (PREVIOUSLY 8% TO 10%) Source text for Eikon
G

GSK shares fall after sales of top two vaccines disappoint

UPDATE 8-GSK shares fall after sales of top two vaccines disappoint Sales for top two vaccines disappoint Cuts vaccine outlook, cites US agency decision on RSV Shares fall as much as 2.2% Raises annual earnings, sales outlook for 2nd time this year Factors hitting vaccine sales are short-term: CEO Adds vaccines concerns from analyst call in paragraph 12 By Yadarisa Shabong and Maggie Fick July 31 (Reuters) - British drugmaker GSK GSK.L cut its forecast for 2024 vaccine sales on Wednesday after q
G
P
U



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.